Nuvelo to Be Featured at the 2004 UBS Global Life Sciences Conference
Why does nuvo pr their presentatations as "featured" and everyone else "to present"? Something a little misleading about that.
re ALXN. Improvement in cognition was once thought to be a benefit of alxn pexilizumab, co imo was purposely vague on this and it turned out no real cog benefit. Cog issue is also prevalent post cancer chemotherapy. A drug for neuro cog associated with cabg or chemo would be a valuable thing imo and certainly as you point out, a pro to a systematic shift ala off pump vs on.
Market Data 
Markets 
AI
